 |
BioWorld-International-2011-06-01
Sticky LDL Research May Lead to Cardiovascular Disease Drugs
Heptares, AstraZeneca GPCR Deal Worth Potential $186M
LONDON – Heptares Ltd. announced a four-year collaboration with AstraZeneca plc worth a potential $186 million, plus funding for research and development. That is the third deal this year around Heptares' stabilized G-protein coupled receptor (GPCR) platform and the first in which the technology will be used for antibody discovery. (BioWorld International)